BRPI0922789A2 - peptídeo de ligação de albumina intermediador para reconhecimento de doença - Google Patents

peptídeo de ligação de albumina intermediador para reconhecimento de doença

Info

Publication number
BRPI0922789A2
BRPI0922789A2 BRPI0922789A BRPI0922789A BRPI0922789A2 BR PI0922789 A2 BRPI0922789 A2 BR PI0922789A2 BR PI0922789 A BRPI0922789 A BR PI0922789A BR PI0922789 A BRPI0922789 A BR PI0922789A BR PI0922789 A2 BRPI0922789 A2 BR PI0922789A2
Authority
BR
Brazil
Prior art keywords
binding peptide
albumin binding
disease
disease recognition
mammal
Prior art date
Application number
BRPI0922789A
Other languages
English (en)
Inventor
Trieu Vuong
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of BRPI0922789A2 publication Critical patent/BRPI0922789A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

peptídeo de ligação de albumina intermediador para reconhecimento de doença a invenção fornece composições e métodos para a entrega de um agente terapêutico ou de diagnóstico para um sítio de doença em um mamífero, o método compreendendo a administração ao mamífero de uma quantidade terapeuticamente ou para diagnóstico eficaz de uma composição farmacêutica, onde a composição farmacêutica compreende o agente terapêutico ou de diagnóstico, aliado de um peptídeo de ligação de albumina e um transportador farmaceuticamente aceitável.
BRPI0922789A 2008-12-05 2009-12-07 peptídeo de ligação de albumina intermediador para reconhecimento de doença BRPI0922789A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12023408P 2008-12-05 2008-12-05
US17036809P 2009-04-17 2009-04-17
PCT/US2009/066943 WO2010065950A2 (en) 2008-12-05 2009-12-07 Albumin binding peptide-mediated disease targeting

Publications (1)

Publication Number Publication Date
BRPI0922789A2 true BRPI0922789A2 (pt) 2019-10-15

Family

ID=42233910

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922789A BRPI0922789A2 (pt) 2008-12-05 2009-12-07 peptídeo de ligação de albumina intermediador para reconhecimento de doença

Country Status (13)

Country Link
US (1) US20120009123A1 (pt)
EP (1) EP2373331A4 (pt)
JP (1) JP5496220B2 (pt)
KR (1) KR101370797B1 (pt)
CN (1) CN102281891A (pt)
AU (1) AU2009322126B2 (pt)
BR (1) BRPI0922789A2 (pt)
CA (3) CA2745899C (pt)
MX (1) MX2011005968A (pt)
NZ (2) NZ606480A (pt)
RU (1) RU2011127422A (pt)
WO (1) WO2010065950A2 (pt)
ZA (1) ZA201104905B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
US10821160B2 (en) 2016-03-01 2020-11-03 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability
RU2019105550A (ru) * 2016-08-05 2020-09-07 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования
CN106220714B (zh) * 2016-09-26 2019-08-09 成都诺恩基因科技有限公司 一种抑制新生血管的多肽、含有该多肽的药物及其应用
JP2020500306A (ja) 2016-11-04 2020-01-09 オーフス ウニベルシテット 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
JP7092546B2 (ja) * 2017-04-27 2022-06-28 ライオン株式会社 骨質評価用マーカーおよびその用途
WO2019055955A1 (en) 2017-09-18 2019-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN
KR102206762B1 (ko) * 2018-03-19 2021-01-25 울산대학교 산학협력단 알부민 결합 나노바디가 융합된 wkymvm 펩티드의 수용성 과발현 및 정제 방법
CN111909275A (zh) * 2019-05-08 2020-11-10 上海大学 延长多肽药物循环半衰期的靶向载药体系及其构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
WO2004074430A2 (en) * 2002-12-06 2004-09-02 Diadexus, Inc. Compositions, splice variants and methods relating to lung specific genes and proteins
WO2004064785A2 (en) * 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
DK2829283T3 (en) * 2003-04-30 2017-09-18 Univ Zuerich METHOD OF TREATING CANCER USING IMMUNOTOXIN
EP1732613A2 (en) * 2004-04-06 2006-12-20 Affibody AB Use of serum albumin binding peptides conjugates for the preparation of a medicament
CN102614521A (zh) * 2004-05-14 2012-08-01 阿布拉西斯生物科学公司 利用白蛋白-结合蛋白作为靶标的治疗方法
US7436389B2 (en) * 2004-07-29 2008-10-14 Eugene J Mar Method and system for controlling the output of a diffractive light device
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof

Also Published As

Publication number Publication date
NZ593311A (en) 2013-03-28
WO2010065950A3 (en) 2010-09-30
AU2009322126A1 (en) 2011-06-30
EP2373331A2 (en) 2011-10-12
CN102281891A (zh) 2011-12-14
CA2745899C (en) 2015-04-28
ZA201104905B (en) 2012-03-28
AU2009322126B2 (en) 2013-06-20
JP5496220B2 (ja) 2014-05-21
WO2010065950A2 (en) 2010-06-10
JP2012511029A (ja) 2012-05-17
CA2893696A1 (en) 2010-06-10
CA2867252A1 (en) 2010-06-10
CA2867252C (en) 2015-09-01
US20120009123A1 (en) 2012-01-12
CA2745899A1 (en) 2010-06-10
NZ606480A (en) 2014-08-29
KR101370797B1 (ko) 2014-03-14
RU2011127422A (ru) 2013-01-10
MX2011005968A (es) 2011-07-19
EP2373331A4 (en) 2015-11-18
CA2893696C (en) 2018-09-04
KR20110117651A (ko) 2011-10-27

Similar Documents

Publication Publication Date Title
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
BR112012026801B8 (pt) conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
GB2496794A (en) Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
NZ593281A (en) Sparc binding peptides and uses thereof
HK1219661A1 (zh) 用於治疗皮肤病的甲酰基肽受体2的激动剂的用途
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
TW200833367A (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
BR112015012497A2 (pt) combinações farmacêuticas
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
WO2009137436A3 (en) Peptide conjugates

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2546 DE 22-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]